Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial
Authors:
- Thomas J GeorgeTGThomas J George
- Tuo LinTLTuo Lin
- Ibrahim NassourINIbrahim Nassour
- Sherise C RogersSRSherise C Rogers
- Tim JangTJTim Jang
- Ilyas SahinISIlyas Sahin
- Brian H RamnaraignBRBrian H Ramnaraign
- Jesus FabregasJFJesus Fabregas
- Kathryn HitchcockKHKathryn Hitchcock
- Gonghao LiuGLGonghao Liu
- Anita A TurkATAnita A Turk
Open Access
- 29 June 2026
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Abstract
Background: While neoadjuvant FOLFIRINOX is an effective regimen for pancreatic ductal adenocarcinoma (PDAC), toxicity frequently limits its use. Nanoliposomal irinotecan (nal-IRI) offers improved pharmacokinetic properties and may mitigate some of the side effects. We conducted a multi-institutional, phase II study to evaluate the safety and clinical activity of neoadjuvant NALIRIFOX (nal-IRI, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with resectable and borderline resectable (R/BR) PDAC. Methods: Patients with untreated R/BR PDAC received eight cycles of neoadjuvant NALIRIFOX. The primary endpoint was the 30-day post-operative major complication rate among resected patients. Secondary endpoints included treatment completion rate, R0 resection rate, objective response rate (ORR), biochemical (CA19-9) and radiographic responses, nodal downstaging, and quality of life (QoL by FACT-G). Results: Of the 45 enrolled patients, 73% completed all eight cycles of neoadjuvant NALIRIFOX. 34 patients (76%) underwent attempted surgery, of whom 29 (64%) had complete resection (15 BR patients and 14 R patients). The 30-day post-operative major complication rate was 10% (95% CI, 2.2–27%, p = 0.012), meeting the pre-specified threshold. R0 resection was achieved in 90% of resected patients. The radiographic ORR was 45% (95% CI, 29–62%), and the clinical benefit rate was 73% (95% CI, 58–85%). Conclusion: Neoadjuvant NALIRIFOX is a safe and active regimen in R/BR PDAC with a low post-operative complication rate, high treatment completion and R0 resection rates, and meaningful clinical responses. These findings support further investigation of NALIRIFOX as part of a total neoadjuvant therapy (TNT) approach in PDAC. [ClinicalTrials.gov identifier: NCT03483038].Keywords
Funding Information
- Cancer Center, University of Florida Health (P30CA247796)
This publication has 20 references indexed in Scilit:
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerJAMA Oncology, 2022
- Neoadjuvant therapy for pancreatic cancerUpdates in Surgery, 2021
- Error in Visual AbstractJAMA Oncology, 2021
- Efficacy of Perioperative Chemotherapy for Resectable Pancreatic AdenocarcinomaJAMA Oncology, 2021
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivorsEuropean Journal of Cancer, 2019
- Preoperative Chemoradiotherapy Potentially Improves Outcome for (Borderline) Resectable Pancreatic Cancer: Preliminary Results of the Dutch Randomized Phase III PREOPANC TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?Journal of Surgical Oncology, 2016
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialThe Lancet, 2016
- Multidisciplinary neoadjuvant management for potentially curable pancreatic cancerCancer Medicine, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009